Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2017-09-23

AUTHORS

Bernard Mouillac , Christiane Mendre

ABSTRACT

Pharmacological chaperones recently opened new possibilities in G protein-coupled receptor drug discovery. Even more interestingly, some unique ligands combine pharmacological chaperoning and biased agonism properties, boosting their therapeutic interest in many human diseases resulting from G protein-coupled receptor mutation and misfolding. These compounds displaying dual characteristics would constitute a perfect treatment for congenital Nephrogenic Diabetes Insipidus, a typical conformational disease. This X-linked genetic pathology is mostly associated with inactivating mutations of the renal arginine-vasopressin V2 receptor leading to misfolding and intracellular retention of the receptor, causing the inability of patients to concentrate their urine in response to the antidiuretic hormone. Cell-permeable pharmacological chaperones have been successfully challenged to restore plasma membrane localization of many V2 receptor mutants. In addition, different classes of specific ligands such as antagonists, agonists as well as biased agonists of the V2 receptor have proven their usefulness in rescuing mutant receptor function. This is particularly relevant for small-molecule biased agonists which only trigger Gs protein activation and cyclic adenosine monophosphate production, the V2-induced signaling pathway responsible for water reabsorption. In parallel, high-throughput screening assays based on receptor trafficking rescue approaches have been developed to discover novel V2 pharmacological chaperone molecules from different chemical libraries. These new hit compounds, which still need to be pharmacologically characterized and functionally tested in vivo, represent promising candidates for the treatment of congenital Nephrogenic Diabetes Insipidus. More... »

PAGES

63-83

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/164_2017_50

DOI

http://dx.doi.org/10.1007/164_2017_50

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091899176

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28939971


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Insipidus, Nephrogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Discovery", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ligands", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Chaperones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteostasis Deficiencies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, G-Protein-Coupled", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vasopressin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut de G\u00e9nomique Fonctionnelle, CNRS, INSERM, Universit\u00e9 de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France", 
          "id": "http://www.grid.ac/institutes/grid.461890.2", 
          "name": [
            "Institut de G\u00e9nomique Fonctionnelle, CNRS, INSERM, Universit\u00e9 de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mouillac", 
        "givenName": "Bernard", 
        "id": "sg:person.01342670232.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342670232.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut de G\u00e9nomique Fonctionnelle, CNRS, INSERM, Universit\u00e9 de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France", 
          "id": "http://www.grid.ac/institutes/grid.461890.2", 
          "name": [
            "Institut de G\u00e9nomique Fonctionnelle, CNRS, INSERM, Universit\u00e9 de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mendre", 
        "givenName": "Christiane", 
        "id": "sg:person.01246653327.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246653327.86"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-09-23", 
    "datePublishedReg": "2017-09-23", 
    "description": "Pharmacological chaperones recently opened new possibilities in G protein-coupled receptor drug discovery. Even more interestingly, some unique ligands combine pharmacological chaperoning and biased agonism properties, boosting their therapeutic interest in many human diseases resulting from G protein-coupled receptor mutation and misfolding. These compounds displaying dual characteristics would constitute a perfect treatment for congenital Nephrogenic Diabetes Insipidus, a typical conformational disease. This X-linked genetic pathology is mostly associated with inactivating mutations of the renal arginine-vasopressin V2 receptor leading to misfolding and intracellular retention of the receptor, causing the inability of patients to concentrate their urine in response to the antidiuretic hormone. Cell-permeable pharmacological chaperones have been successfully challenged to restore plasma membrane localization of many V2 receptor mutants. In addition, different classes of specific ligands such as antagonists, agonists as well as biased agonists of the V2 receptor have proven their usefulness in rescuing mutant receptor function. This is particularly relevant for small-molecule biased agonists which only trigger Gs protein activation and cyclic adenosine monophosphate production, the V2-induced signaling pathway responsible for water reabsorption. In parallel, high-throughput screening assays based on receptor trafficking rescue approaches have been developed to discover novel V2 pharmacological chaperone molecules from different chemical libraries. These new hit compounds, which still need to be pharmacologically characterized and functionally tested in vivo, represent promising candidates for the treatment of congenital Nephrogenic Diabetes Insipidus.", 
    "editor": [
      {
        "familyName": "Ulloa-Aguirre", 
        "givenName": "Alfredo", 
        "type": "Person"
      }, 
      {
        "familyName": "Tao", 
        "givenName": "Ya-Xiong", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/164_2017_50", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-74163-5", 
        "978-3-319-74164-2"
      ], 
      "name": "Targeting Trafficking in Drug Development", 
      "type": "Book"
    }, 
    "keywords": [
      "congenital nephrogenic diabetes insipidus", 
      "pharmacological chaperones", 
      "G protein-coupled receptor mutation", 
      "G protein-coupled receptor drug discovery", 
      "plasma membrane localization", 
      "typical conformational disease", 
      "nephrogenic diabetes insipidus", 
      "receptor drug discovery", 
      "different chemical libraries", 
      "high-throughput screening assays", 
      "Gs protein activation", 
      "diabetes insipidus", 
      "membrane localization", 
      "conformational diseases", 
      "receptor mutants", 
      "mutant receptor function", 
      "V2 receptors", 
      "new hit compounds", 
      "pharmacological chaperoning", 
      "protein activation", 
      "chaperone molecules", 
      "chaperones", 
      "human diseases", 
      "inability of patients", 
      "rescue approach", 
      "cyclic adenosine monophosphate (cAMP) production", 
      "potential therapeutic strategy", 
      "chemical libraries", 
      "adenosine monophosphate production", 
      "receptor function", 
      "biased agonists", 
      "drug discovery", 
      "specific ligands", 
      "unique ligand", 
      "screening assays", 
      "hit compounds", 
      "antidiuretic hormone", 
      "therapeutic strategies", 
      "receptor mutations", 
      "mutations", 
      "monophosphate production", 
      "perfect treatment", 
      "genetic pathology", 
      "therapeutic interest", 
      "vasopressin receptors", 
      "water reabsorption", 
      "agonists", 
      "receptors", 
      "chaperoning", 
      "insipidus", 
      "mutants", 
      "misfolding", 
      "disease", 
      "treatment", 
      "pathway", 
      "ligands", 
      "patients", 
      "different classes", 
      "antagonist", 
      "activation", 
      "assays", 
      "vivo", 
      "localization", 
      "pathology", 
      "hormone", 
      "reabsorption", 
      "discovery", 
      "urine", 
      "library", 
      "molecules", 
      "production", 
      "compounds", 
      "function", 
      "response", 
      "new possibilities", 
      "inability", 
      "usefulness", 
      "addition", 
      "candidates", 
      "dual characteristics", 
      "retention", 
      "strategies", 
      "promising candidate", 
      "class", 
      "possibility", 
      "characteristics", 
      "interest", 
      "approach", 
      "properties"
    ], 
    "name": "Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors", 
    "pagination": "63-83", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091899176"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/164_2017_50"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28939971"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/164_2017_50", 
      "https://app.dimensions.ai/details/publication/pub.1091899176"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_60.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/164_2017_50"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/164_2017_50'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/164_2017_50'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/164_2017_50'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/164_2017_50'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      22 PREDICATES      125 URIs      116 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/164_2017_50 schema:about N02df6fcefc0d48b199b91a26719579ea
2 N208ba780748a49ffb708845afc82dc40
3 N87dd808a916744c8b2ceb527ea73e8e6
4 N8ed0356cd5544bc59d6c45d144833367
5 Nd759e72b314b4c988e6395682bbdbd3b
6 Ne78128d975334d1db7b0c345985c1596
7 Neabb818d478049f2bd9e5a39838f25d0
8 Nf847cfa4eddd46099c066030c75440aa
9 Nffc61d8fe79b4c929a6ef00221b09082
10 anzsrc-for:06
11 anzsrc-for:0601
12 anzsrc-for:11
13 anzsrc-for:1115
14 schema:author N83d42b04a9374eee82e16a75d3155d5b
15 schema:datePublished 2017-09-23
16 schema:datePublishedReg 2017-09-23
17 schema:description Pharmacological chaperones recently opened new possibilities in G protein-coupled receptor drug discovery. Even more interestingly, some unique ligands combine pharmacological chaperoning and biased agonism properties, boosting their therapeutic interest in many human diseases resulting from G protein-coupled receptor mutation and misfolding. These compounds displaying dual characteristics would constitute a perfect treatment for congenital Nephrogenic Diabetes Insipidus, a typical conformational disease. This X-linked genetic pathology is mostly associated with inactivating mutations of the renal arginine-vasopressin V2 receptor leading to misfolding and intracellular retention of the receptor, causing the inability of patients to concentrate their urine in response to the antidiuretic hormone. Cell-permeable pharmacological chaperones have been successfully challenged to restore plasma membrane localization of many V2 receptor mutants. In addition, different classes of specific ligands such as antagonists, agonists as well as biased agonists of the V2 receptor have proven their usefulness in rescuing mutant receptor function. This is particularly relevant for small-molecule biased agonists which only trigger Gs protein activation and cyclic adenosine monophosphate production, the V2-induced signaling pathway responsible for water reabsorption. In parallel, high-throughput screening assays based on receptor trafficking rescue approaches have been developed to discover novel V2 pharmacological chaperone molecules from different chemical libraries. These new hit compounds, which still need to be pharmacologically characterized and functionally tested in vivo, represent promising candidates for the treatment of congenital Nephrogenic Diabetes Insipidus.
18 schema:editor N013c80bf9da54332ad1bb827cbc31589
19 schema:genre chapter
20 schema:isAccessibleForFree false
21 schema:isPartOf N2d9a9839bb774a3788c47d7e3f8f5184
22 schema:keywords G protein-coupled receptor drug discovery
23 G protein-coupled receptor mutation
24 Gs protein activation
25 V2 receptors
26 activation
27 addition
28 adenosine monophosphate production
29 agonists
30 antagonist
31 antidiuretic hormone
32 approach
33 assays
34 biased agonists
35 candidates
36 chaperone molecules
37 chaperones
38 chaperoning
39 characteristics
40 chemical libraries
41 class
42 compounds
43 conformational diseases
44 congenital nephrogenic diabetes insipidus
45 cyclic adenosine monophosphate (cAMP) production
46 diabetes insipidus
47 different chemical libraries
48 different classes
49 discovery
50 disease
51 drug discovery
52 dual characteristics
53 function
54 genetic pathology
55 high-throughput screening assays
56 hit compounds
57 hormone
58 human diseases
59 inability
60 inability of patients
61 insipidus
62 interest
63 library
64 ligands
65 localization
66 membrane localization
67 misfolding
68 molecules
69 monophosphate production
70 mutant receptor function
71 mutants
72 mutations
73 nephrogenic diabetes insipidus
74 new hit compounds
75 new possibilities
76 pathology
77 pathway
78 patients
79 perfect treatment
80 pharmacological chaperones
81 pharmacological chaperoning
82 plasma membrane localization
83 possibility
84 potential therapeutic strategy
85 production
86 promising candidate
87 properties
88 protein activation
89 reabsorption
90 receptor drug discovery
91 receptor function
92 receptor mutants
93 receptor mutations
94 receptors
95 rescue approach
96 response
97 retention
98 screening assays
99 specific ligands
100 strategies
101 therapeutic interest
102 therapeutic strategies
103 treatment
104 typical conformational disease
105 unique ligand
106 urine
107 usefulness
108 vasopressin receptors
109 vivo
110 water reabsorption
111 schema:name Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors
112 schema:pagination 63-83
113 schema:productId N1336c5d3b93c4def8b5817e59c6a3224
114 Nc2be8517dd224dbca49eac713971802a
115 Nfe0eec435ec14e38ae49b521fd5243a4
116 schema:publisher N1f80429f226e48d9ba627bb474de0921
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091899176
118 https://doi.org/10.1007/164_2017_50
119 schema:sdDatePublished 2022-12-01T06:55
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher Nd03dfffa5152497192c5764f91b075fb
122 schema:url https://doi.org/10.1007/164_2017_50
123 sgo:license sg:explorer/license/
124 sgo:sdDataset chapters
125 rdf:type schema:Chapter
126 N013c80bf9da54332ad1bb827cbc31589 rdf:first Nc965efc974cc45b3aac8bae7bcb4f04d
127 rdf:rest Ne1e92e73f0a64804898ffdae049f94e6
128 N02df6fcefc0d48b199b91a26719579ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Drug Discovery
130 rdf:type schema:DefinedTerm
131 N1336c5d3b93c4def8b5817e59c6a3224 schema:name dimensions_id
132 schema:value pub.1091899176
133 rdf:type schema:PropertyValue
134 N15fd198a5e73472c8b309a1dbe6628b7 rdf:first sg:person.01246653327.86
135 rdf:rest rdf:nil
136 N1f80429f226e48d9ba627bb474de0921 schema:name Springer Nature
137 rdf:type schema:Organisation
138 N208ba780748a49ffb708845afc82dc40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Molecular Chaperones
140 rdf:type schema:DefinedTerm
141 N2d9a9839bb774a3788c47d7e3f8f5184 schema:isbn 978-3-319-74163-5
142 978-3-319-74164-2
143 schema:name Targeting Trafficking in Drug Development
144 rdf:type schema:Book
145 N83d42b04a9374eee82e16a75d3155d5b rdf:first sg:person.01342670232.37
146 rdf:rest N15fd198a5e73472c8b309a1dbe6628b7
147 N87dd808a916744c8b2ceb527ea73e8e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Receptors, G-Protein-Coupled
149 rdf:type schema:DefinedTerm
150 N8ed0356cd5544bc59d6c45d144833367 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 Nb9c408f5693243e4bce183c90756b969 schema:familyName Tao
154 schema:givenName Ya-Xiong
155 rdf:type schema:Person
156 Nc2be8517dd224dbca49eac713971802a schema:name doi
157 schema:value 10.1007/164_2017_50
158 rdf:type schema:PropertyValue
159 Nc965efc974cc45b3aac8bae7bcb4f04d schema:familyName Ulloa-Aguirre
160 schema:givenName Alfredo
161 rdf:type schema:Person
162 Nd03dfffa5152497192c5764f91b075fb schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 Nd759e72b314b4c988e6395682bbdbd3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Diabetes Insipidus, Nephrogenic
166 rdf:type schema:DefinedTerm
167 Ne1e92e73f0a64804898ffdae049f94e6 rdf:first Nb9c408f5693243e4bce183c90756b969
168 rdf:rest rdf:nil
169 Ne78128d975334d1db7b0c345985c1596 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Receptors, Vasopressin
171 rdf:type schema:DefinedTerm
172 Neabb818d478049f2bd9e5a39838f25d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Mutation
174 rdf:type schema:DefinedTerm
175 Nf847cfa4eddd46099c066030c75440aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Proteostasis Deficiencies
177 rdf:type schema:DefinedTerm
178 Nfe0eec435ec14e38ae49b521fd5243a4 schema:name pubmed_id
179 schema:value 28939971
180 rdf:type schema:PropertyValue
181 Nffc61d8fe79b4c929a6ef00221b09082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Ligands
183 rdf:type schema:DefinedTerm
184 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
185 schema:name Biological Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
188 schema:name Biochemistry and Cell Biology
189 rdf:type schema:DefinedTerm
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
194 schema:name Pharmacology and Pharmaceutical Sciences
195 rdf:type schema:DefinedTerm
196 sg:person.01246653327.86 schema:affiliation grid-institutes:grid.461890.2
197 schema:familyName Mendre
198 schema:givenName Christiane
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246653327.86
200 rdf:type schema:Person
201 sg:person.01342670232.37 schema:affiliation grid-institutes:grid.461890.2
202 schema:familyName Mouillac
203 schema:givenName Bernard
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342670232.37
205 rdf:type schema:Person
206 grid-institutes:grid.461890.2 schema:alternateName Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France
207 schema:name Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, 141 rue de la cardonille, 34094, Montpellier Cedex 05, France
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...